NCT07023484 Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 126 participants in total. It began in 2025-05-22 with a primary completion date of 2028-12-31.

Brief Summary

About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.

Eligibility Criteria

Inclusion Criteria: 1. Patients aged 18 years old or older 2. Patients with Eastern Cooperative Oncology Group score 0-1 within 28 days prior to recruitment 3. Patients who can sign the informed consent 4. Patients with stage III-IV histologically or cytologically confirmed epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer not amenable for PDS 5. Patients who have baseline computed tomography (CT) of thorax, abdomen and pelvis. 6. Patients who are planned for neoadjuvant chemotherapy (NACT) using 3-weekly carboplatin and paclitaxel. Those who have received one cycle of NACT may be eligible if the CA125 schedule of the study group can be matched. 7. Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal) 8. Patients who agree for chemotherapy and interval debulking surgery (IDS) if the disease becomes operable after NACT 9. Patients with adequate hematologic, liver and renal functions for chemotherapy 10. Patients who agree to receive adjuvant chemotherapy after IDS. The total number of NACT and adjuvant chemotherapy should be four or above, up to maximum of 9 cycles. 11. Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment. 12. Patients must have either germline and / or somatic BRCA test, or homologous recombination deficiency (HRD) test. Exclusion Criteria: 1. Patients who have borderline malignancy, or non-EOC like germ cell or sex cord tumor, or metastatic diseases from other origins 2. Patients with mucinous and neuroendocrine histology 3. Patients with history of other malignancies within five years 4. Patients who are eligible for primary debulking surgery (PDS) 5. Patients who cannot undergo PDS because of parametrial and/or vaginal involvement alone 6. Patients who are not fit for PDS because of medical morbidities or refusal of operation 7. Patients who have already started NACT outside the study centers, except those who have received only one cycle within 7 days and the baseline CA125 value within 3 days of NACT (normal cut-off 35 U/ml) is available 8. Patients who participate in other interventional studies 9. Patients who are pregnant or breastfeeding 10. Patients who have contraindications to platinum-based chemotherapy 11. Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.